Alnylam Pharmaceuticals_ALN-TTR02-014_APOLLO EAP

Summary

The objective of the study is to assess the long-term safety of patisiran in patients with ATTR amyloidosis with cardiomyopathy as assessed by a review of adverse events (AEs).


Inclusion Criteria

Not Available


Study Location(s)

Beverly


Full Title

Expanded Access Protocol to Provide Patisiran to Patients with Transthyretin-mediated Amyloidosis with Cardiomyopathy

Details
Disease Type/Condition

Other

Principal Investigator

Patel, Jignesh

Age Group

Adult

Phase

N/A

IRB Number

STUDY00002065


Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Other

Principal Investigator

Patel, Jignesh

Age Group

Adult

Phase

N/A

IRB Number

ALN-TTR02-014


Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?